Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ecopetrol SA (EC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ecopetrol SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Ecopetrol SA trades at $15.69 (market cap $29.34B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Ecopetrol SA pays a 4.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EC | |
|---|---|---|
Market Cap | $39.89B | $29.34B |
Sector | Health | Energy |
52-Week High | $491.22 | $16.58 |
52-Week Low | $278.09 | $8.29 |
Enterprise Value | $38.15B | $57.13B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Ecopetrol (EC) trades at $15.58, up 1.23% with bullish technical signals from moving averages. The stock shows mixed fundamentals with declining revenue from $159.6B in 2022 to $119.7B in 2025, though maintains stable 8.76% net margins. Recent corporate developments include a $0.66 dividend payment and S&P credit rating affirmation at BB- with stable outlook as of June 17, 2026.
EC presents a cautious opportunity with attractive valuation multiples (P/E 11.1, P/S 0.97) but faces revenue headwinds. Analyst consensus is mixed with 27% buy ratings and $14.63 target below current price. Key risks include energy price volatility and execution challenges amid declining cash flows from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
